{"id":"W4295836973","doi":"10.1016/j.annonc.2022.07.1551","title":"1448O Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) + lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"","keywords":"Lenvatinib; Medicine; Pembrolizumab; Renal cell carcinoma; Internal medicine; Oncology; Cancer research; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001207563,0.001270518,0.001928137,0.0004291587,0.0004741566,0.001354985,0.0008708386,0.001331641,0.01127029],"category_scores_gemma":[0.0007180041,0.0005973775,0.001603568,0.0003497257,0.0006252099,0.0008319519,0.0003850739,0.00419291,0.00254554],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001025313,"about_ca_system_score_gemma":0.001719983,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001647485,"about_ca_topic_score_gemma":0.00485765,"domain_scores_codex":[0.9997086,0.0001072366,0.00001169542,0.00005714317,0.00003191523,0.00008340387],"domain_scores_gemma":[0.9995803,0.00004985549,0.00005330357,0.00003168331,0.00003100573,0.0002539457],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.672086,0.06340029,0.004902308,0.002027658,0.00274942,0.000240319,0.0003256574,0.003535802,0.0394344,0.001144065,0.02440378,0.1857503],"study_design_scores_gemma":[0.7313655,0.2423298,0.007577974,0.00009822946,0.0008615124,0.0002952179,0.00008371338,0.0013516,0.002876896,0.000470787,0.01265322,0.00003556248],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9666162,0.006745828,0.001086539,0.001975879,0.000901484,0.004451484,0.006242945,0.000325032,0.01165466],"genre_scores_gemma":[0.9485682,0.006170426,0.00460945,0.003446145,0.0004278559,0.004071388,0.0111985,0.0001441706,0.02136372],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01127029,"threshold_uncertainty_score":0.03770286,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.10989365781455,"score_gpt":0.3830376886139772,"score_spread":0.2731440307994272,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}